Biotechnology company BioLamina is targeting a US expansion with plans to open an office in Boston.
The company will open an office in Boston, MA, to help it better support existing and new customers in the US and enable it to collaborate with science hubs in the region.
The Boston office will complement the Swedish headquarters just outside Stockholm and will focus on driving new business and the development of commercial operations in the US. BioLamina plans to begin operations in September 2022 and will begin recruiting for key commercial roles in the US organisation.
BioLamina is also currently expanding its manufacturing capacity by building a new production and R&D facility to meet demands within the cell therapy field, among other sectors.
Veronica Byfield Sköld, CEO of BioLamina said: “Our products solve difficult problems for our customers and help them to develop new therapies. Expanding to the US is a key step in ensuring that our products can contribute as far as possible within their recognised applications, as well as for realising other possibilities of our matrices. Establishing an office in the Boston-Cambridge area not only brings us closer to our customers but will also open new opportunities for collaboration and market openings.”